Fate Therapeutics Net Worth
Fate Therapeutics Net Worth Breakdown | FATE |
Fate Therapeutics Net Worth Analysis
Fate Therapeutics' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Fate Therapeutics' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Fate Therapeutics' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Fate Therapeutics' net worth analysis. One common approach is to calculate Fate Therapeutics' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Fate Therapeutics' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Fate Therapeutics' net worth. This approach calculates the present value of Fate Therapeutics' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Fate Therapeutics' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Fate Therapeutics' net worth. This involves comparing Fate Therapeutics' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Fate Therapeutics' net worth relative to its peers.
Enterprise Value |
|
To determine if Fate Therapeutics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Fate Therapeutics' net worth research are outlined below:
| Fate Therapeutics generated a negative expected return over the last 90 days | |
| Fate Therapeutics has high historical volatility and very poor performance | |
| Fate Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 63.53 M. Net Loss for the year was (160.93 M) with loss before overhead, payroll, taxes, and interest of (224.15 M). | |
| Fate Therapeutics currently holds about 568.85 M in cash with (132.26 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.86, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Fate Therapeutics has a poor financial position based on the latest SEC disclosures | |
| Over 94.0% of the company shares are owned by institutional investors | |
| Latest headline from news.google.com: Fate Therapeutics As Its Rally Fizzles, We May Be Near The Bottom - Seeking Alpha |
Fate Therapeutics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Fate Therapeutics. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Fate Therapeutics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 27th of February 2024 Upcoming Quarterly Report | View | |
| 1st of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 27th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Know Fate Therapeutics' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Fate Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Fate Therapeutics backward and forwards among themselves. Fate Therapeutics' institutional investor refers to the entity that pools money to purchase Fate Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Casdin Capital, Llc | 2023-12-31 | 2 M | Citadel Advisors Llc | 2023-09-30 | 2 M | Two Sigma Advisers, Llc | 2023-12-31 | 1.9 M | Geode Capital Management, Llc | 2023-12-31 | 1.9 M | State Street Corporation | 2023-12-31 | 1.9 M | Federated Hermes Inc | 2023-12-31 | 1.8 M | Adage Capital Partners Gp Llc | 2023-12-31 | 1.7 M | Two Sigma Investments Llc | 2023-12-31 | 1.6 M | Morgan Stanley - Brokerage Accounts | 2023-12-31 | 1.3 M | Redmile Group, Llc | 2023-09-30 | 13.1 M | Blackrock Inc | 2023-12-31 | 11.2 M |
Follow Fate Therapeutics' market capitalization trends
The company currently falls under 'Small-Cap' category with a current market capitalization of 459.68 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Fate Therapeutics's market, we take the total number of its shares issued and multiply it by Fate Therapeutics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.Market Cap |
|
Project Fate Therapeutics' profitablity
Fate Therapeutics' profitability indicators refer to fundamental financial ratios that showcase Fate Therapeutics' ability to generate income relative to its revenue or operating costs. If, let's say, Fate Therapeutics is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Fate Therapeutics' executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Fate Therapeutics' profitability requires more research than a typical breakdown of Fate Therapeutics' financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.32) | (0.33) | |
| Return On Capital Employed | (0.38) | (0.40) | |
| Return On Assets | (0.32) | (0.33) | |
| Return On Equity | (0.44) | (0.46) |
When accessing Fate Therapeutics' net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Fate Therapeutics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Fate Therapeutics' profitability and make more informed investment decisions.
The data published in Fate Therapeutics' official financial statements usually reflect Fate Therapeutics' business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Fate Therapeutics. For example, before you start analyzing numbers published by Fate accountants, it's critical to develop an understanding of what Fate Therapeutics' liquidity, profitability, and earnings quality are in the context of the Biotechnology space in which it operates.
Please note, the presentation of Fate Therapeutics' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Fate Therapeutics' management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Fate Therapeutics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Fate Therapeutics. Please utilize our Beneish M Score to check the likelihood of Fate Therapeutics' management manipulating its earnings.
Evaluate Fate Therapeutics' management efficiency
Fate Therapeutics has return on total asset (ROA) of (0.1832) % which means that it has lost $0.1832 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.3776) %, meaning that it created substantial loss on money invested by shareholders. Fate Therapeutics' management efficiency ratios could be used to measure how well Fate Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of May 1, 2024, Return On Tangible Assets is expected to decline to -0.33. In addition to that, Return On Capital Employed is expected to decline to -0.4. At present, Fate Therapeutics' Other Current Assets are projected to increase significantly based on the last few years of reporting. The current year's Net Tangible Assets is expected to grow to about 584.4 M, whereas Non Currrent Assets Other are forecasted to decline to 8,549.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 3.74 | 1.90 | |
| Net Current Asset Value | 0.00 | 0.00 | |
| Tangible Asset Value | 0.00 | 0.00 | |
| Tangible Book Value Per Share | 3.74 | 1.90 | |
| Enterprise Value Over EBITDA | (2.70) | (2.83) | |
| Price Book Value Ratio | 1.00 | 0.95 | |
| Enterprise Value Multiple | (2.70) | (2.83) | |
| Price Fair Value | 1.00 | 0.95 | |
| Enterprise Value | 429.7 M | 408.2 M |
The analysis of Fate Therapeutics' management efficiency is an essential part of evaluating and assessing the financial and operational performance of the entity. It is also vital to analyze Fate Therapeutics' future growth prospects and the overall market conditions to determine the value and potential of its stock. The analysis involves studying a range of financial metrics such as revenue, earnings, profit margins, cash flow, debt, market share, and external factors such as economic trends, industry outlook, competition, and government regulations. The goal of Fate Stock analysis is to determine whether it is undervalued, fairly valued, or overvalued and to make informed investment decisions.
Enterprise Value Revenue 7.0204 | Revenue 63.5 M | Quarterly Revenue Growth (0.96) | Revenue Per Share 0.646 | Return On Equity (0.38) |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Fate Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Fate Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Fate Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Powl Brian T. over a week ago Disposition of 3854 shares by Powl Brian T. of Fate Therapeutics at 4.87 subject to Rule 16b-3 | ||
Redmile Group, Llc over two weeks ago Acquisition by Redmile Group, Llc of 8650 shares of Fate Therapeutics subject to Rule 16b-3 | ||
Redmile Group, Llc over a month ago Acquisition by Redmile Group, Llc of 3636364 shares of Fate Therapeutics at 0.001 subject to Rule 16b-3 | ||
Wolchko J Scott over two months ago Exercise or conversion by Wolchko J Scott of 30000 shares of Fate Therapeutics subject to Rule 16b-3 | ||
Wolchko J Scott over three months ago Sale by Wolchko J Scott of 14391 shares of Fate Therapeutics | ||
Xu Yuan over six months ago Sale by Xu Yuan of 632 shares of Fate Therapeutics | ||
Xu Yuan over six months ago Sale by Xu Yuan of 3460 shares of Fate Therapeutics | ||
Xu Yuan over six months ago Acquisition by Xu Yuan of 40000 shares of Fate Therapeutics subject to Rule 16b-3 | ||
Xu Yuan over a year ago Acquisition by Xu Yuan of 11893 shares of Fate Therapeutics subject to Rule 16b-3 |
Fate Therapeutics Corporate Filings
| 26th of April 2024 Other Reports | ViewVerify | |
| 18th of April 2024 Other Reports | ViewVerify | |
| 16th of April 2024 Other Reports | ViewVerify | |
F3 | 25th of March 2024 An amendment to the original Schedule 13D filing | ViewVerify |
Fate Therapeutics Earnings per Share Projection vs Actual
Be your own money manager
Our tools can tell you how much better you can do entering a position in Fate Therapeutics without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Risk-Return Analysis Now
Risk-Return AnalysisView associations between returns expected from investment and the risk you assume |
| All Next | Launch Module |
Fate Therapeutics Corporate Directors
Fate Therapeutics corporate directors refer to members of a Fate Therapeutics board of directors. The board of directors generally takes responsibility for the Fate Therapeutics' affairs and long-term direction of the entity. A corporate director does not make decisions for the corporation on his own. As a member of the board of directors, she or he must function as a part of a group that makes decisions on behalf of the business only by the board of directors' meetings. To pass a resolution, a majority of Fate Therapeutics' board members must vote for the resolution. The Fate Therapeutics board of directors' duties also include the election, removal, and supervision of officers, including the adoption, amendment, and repeal of bylaws.| Robert Epstein | Director | Profile | |
| Michael Lee | Director | Profile | |
| Shefali Agarwal | Director | Profile | |
| Timothy Coughlin | Independent Director | Profile |
How to buy Fate Stock?
The net worth of Fate Therapeutics is the difference between its total assets and liabilities. Fate Therapeutics' net worth represents the value of the company's equity or ownership interest. In other words, it is the amount of money that would be left over if all of Fate Therapeutics' assets were sold and all of its debts were paid off. Net worth is sometimes referred to as shareholder's equity or book value. Fate Therapeutics' net worth can be used as a measure of its financial health and stability which can help investors to decide if Fate Therapeutics is a good investment. It is also essential in determining the company's creditworthiness and ability to secure financing before investing in Fate Therapeutics stock.Already Invested in Fate Therapeutics?
The danger of trading Fate Therapeutics is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Fate Therapeutics is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Fate Therapeutics. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Fate Therapeutics is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Fate Therapeutics is a strong investment it is important to analyze Fate Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Fate Therapeutics' future performance. For an informed investment choice regarding Fate Stock, refer to the following important reports: Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Fate Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate. For information on how to trade Fate Stock refer to our How to Trade Fate Stock guide.You can also try the Funds Screener module to find actively-traded funds from around the world traded on over 30 global exchanges.
Complementary Tools for Fate Stock analysis
When running Fate Therapeutics' price analysis, check to measure Fate Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Fate Therapeutics is operating at the current time. Most of Fate Therapeutics' value examination focuses on studying past and present price action to predict the probability of Fate Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Fate Therapeutics' price. Additionally, you may evaluate how the addition of Fate Therapeutics to your portfolios can decrease your overall portfolio volatility.
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios |
Is Fate Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Fate Therapeutics. If investors know Fate will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Fate Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.64) | Revenue Per Share 0.646 | Quarterly Revenue Growth (0.96) | Return On Assets (0.18) | Return On Equity (0.38) |
The market value of Fate Therapeutics is measured differently than its book value, which is the value of Fate that is recorded on the company's balance sheet. Investors also form their own opinion of Fate Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Fate Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Fate Therapeutics' market value can be influenced by many factors that don't directly affect Fate Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Fate Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Fate Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Fate Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.